CCM
AQST icon

CAAS Capital Management’s Aquestive Therapeutics AQST Stock Holding History

CAAS Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-217,091
Closed -$862K – 936
2021
Q2 		$862K Buy
+217,091
New +$867K 0.01% 620

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $5.53B AUM 25.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LI
Latash Investments Anchorage, Alaska $136M AUM 9.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CAAS Capital Management's AQST Position: Q3 2021 in Review

CAAS Capital Management sold out of Aquestive Therapeutics (AQST) in Q3 2021, closing a stake of 217,091 shares — an estimated $862K sold.

CAAS Capital Management first reported a position in AQST in Q2 2021 and held it in 1 quarter. The position peaked at $862K in Q2 2021. 46 funds tracked by Wall St. Rank hold AQST as of Q3 2021.

  • CAAS Capital Management reported no remaining Aquestive Therapeutics position as of Q3 2021 after selling out during the quarter.
  • CAAS Capital Management sold 217,091 Aquestive Therapeutics shares in Q3 2021, an estimated $862K.
  • CAAS Capital Management first reported a position in Aquestive Therapeutics in Q2 2021 and held it in 1 quarter.
  • CAAS Capital Management's Aquestive Therapeutics position peaked at $862K in Q2 2021.
  • 46 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2021.

Based on CAAS Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.